preloader

BIG time for baby

Intro text: 

The majority of young women with early breast cancer have hormone-sensitive, or estrogen receptor-positive (ER+) disease, meaning the cancer cells are fed by their own hormones. These women are therefore treated with endocrine therapy, that blocks natural production of hormones in order to reduce risks of the cancer returning. Endocrine therapy may be prescribed for 5-10 years and impacts the ovaries, preventing conception while on treatment.

About 15% of patients with breast cancer are diagnosed during their reproductive years.

A Baby after Breast Cancer

In 2013, Zoë was diagnosed with hormone-sensitive breast cancer. After fighting the disease, she now dreams of becoming a mother.

But Zoë is confronted with an unpleasant dilemma: can the hormonal treatment be paused for up to two years to allow for conception without increasing the risk of breast cancer recurrence?

Today, doctors cannot answer this question based on solid scientific evidence… Zoë needs to know.

Why do we need this BIG Time for Baby study?

BIG Time for Baby is an international clinical study that aims to find an answer to this important question. This represents a unique opportunity to allow young women who have had hormone sensitive breast cancer to plan and try to become pregnant without waiting many years after completing their endocrine treatment. It will also improve our scientific understanding of issues related to conception and pregnancy in young women who have had breast cancer by helping us obtain solid data about whether endocrine therapy can be interrupted without increasing the risk of breast cancer recurrence.

The study will enroll up to 500 women with hormone-sensitive breast cancer to answer this important question.

It costs 21 euro per week (3 euro per day) per participant to carry out the study. Your donation will be used to cover the costs involved and ultimately provide solid answers to critical questions for future generations.

Why donate?

The BIG Time for Baby study will give young women with hormone-sensitive breast cancer the opportunity to try for a baby.

Everybody knows about the story of the stork delivering babies to people’s houses. Everyone can now join the campaign and just, like the stork, bring good luck and hopefully babies to women that are fighting the return of breast cancer.

Donate today

Professor Martine Piccart, oncology expert and president of BIG against breast cancer, stresses the societal importance of this study: “The research associated with pregnancy after breast cancer is limited, making it challenging for a woman to navigate her fertility options. This study is of vital importance – the results will allow to determine the risk of interrupting hormonal treatment for ER+ breast cancer on solid scientific ground, in order to give time to the patient to try for a baby. This information is of great importance to thousands of women worldwide!

About 100,000 women under 42 are diagnosed with hormone sensitive breast cancer every year. They will benefit from the conclusions of the BIG Time for Baby study and be able to make a well-informed choice about pregnancy.

How does the study work?

If you are interested in a more detailed description of this important project, watch this video where Dr Partridge (POSITIVE co-chair for US through ALLIANCE, Rochester, Minnesota) and Dr Pagani (POSITIVE co-chair for International Breast Cancer Study Group, Bern, Switzerland) talk to ecancertv about the POSITIVE study.